Name: CJC-1295 no DAC
Brand: Mindful Research
Price: 58.0 USD
Availability: InStock

CJC-1295 no DAC

$58.00

Shipping calculated at checkout.

Size 5 MG

Quantity 1 VIAL 2 VIALS 5 VIALS 10 VIALS

Quantity

For research use only. Not for human or animal consumption. Purchase implies acknowledgement of these restrictions. No medical or dietary applications. All products are research chemicals and must be handled by qualified professionals.

Test Reports

5 MG - CJNJ312 - 04/03/2025

Properties

Name:	CJC-1295 no DAC/Mod GRF (1-29)
Vial Contents:	Lyophilized Powder
CAS Number:	863288-34-0
PubChem CID:	56841945
Molecular Weight:	3367.954 g/mol
Molecular Formula:	C₁₅₂H₂₅₂N₄₄O₄₂

Source: PubChem

CJC-1295 no DAC - Mod GRF (1-29) Peptide Synopsis

Modified GRF (1-29), also known as CJC-1295 no DAC, is a shortened peptide analogue of growth hormone releasing hormone (GHRH), first created in the 1980s. Studies have demonstrated its potential to enhance muscle growth and repair, expedite wound healing, fortify bones, boost fat burning, and optimize metabolism. Additionally, it may have advantageous impacts on blood sugar management and immune function.

Source: Pubchem

CJC-1295 no DAC - Mod GRF (1-29) Peptide Research

What is it?

Modified GRF (1-29) is a synthetic peptide analog of growth-hormone-releasing hormone (GHRH), first developed in the 1980s. It was found that the first 29 amino acids of GHRH contain all the essential functions of the full 44-amino-acid protein. The original protein, known as GRF (1-29), is the smallest fragment of GHRH that retains its properties. Another truncated synthetically modified form of GHRH, known as Sermorelin or GRF 1-29, also contains 29 amino acids. Modified GRF (1-29) has an added modification of four substituted amino acids to prevent degradation and oxidation during production, transportation, and in vivo use. Additionally, this modification increases its affinity to the GHRH receptors.

Cardiovascular Function

According to studies on rodents, altered GRF and similar GHRH compounds may enhance cardiac function after a heart attack. This could greatly benefit those with heart failure by increasing longevity and improving overall well-being. This discovery has potential applications for conditions such as pulmonary hypertension, congenital heart defects, and other forms of heart disease.

GI System

Past research showed potential benefits of GH in treating Crohn's disease, short bowel syndrome, and inflammatory bowel conditions, but the negative side effects of long-term use overshadowed these advantages. As a result, researchers explored GHRH analogues as a potential alternative. Studies in primates revealed that mod GRF has a positive impact on bowel motility, as it interacts with VIP receptors and improves smooth muscle function in the gastrointestinal and reproductive systems. This is particularly significant for treating constipation-related inflammatory bowel diseases, which can cause significant morbidity and currently have limited treatment options available.

Thyroid & GH

Complications with the thyroid gland are frequently connected to concurrent difficulties in the release of GH. In order to explore this correlation, researchers administered modified growth hormone-releasing factor to individuals with hypothyroidism. The results showed that subjects given thyroid replacement hormone exhibited more pronounced responses to GRF, establishing a clear connection between thyroid hormone and GH. This is only one example of how peptides such as modified GRF can aid scientists in gaining a deeper understanding of human physiology. Mouse models have shown the potential benefits of CJC-1295 no DAC with minimal side effects & high bioavailability through subcutaneous ingestion.